Imagion Biosystems Limited (IBX.AX)

0.0130 -0.0010 (-7.14%) At close: 02:54PM AEST

Imagion Biosystems Limited

5601 Oberlin Drive
Suite 100
San Diego, CA 92121
United States
855 564 5264
https://imagionbiosystems.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Geoff Hollis AGIA, BComm, CA	CFO & Company Sec.	299.83k	N/A	N/A
Dr. Yalia Jayalakshmi Ph.D.	Chief Devel. Officer	479.51k	N/A	N/A
Dr. Isaac J. Bright M.D.	MD & CEO	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.

Corporate governance

Imagion Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.